Last reviewed · How we verify

Prepandrix™ — Competitive Intelligence Brief

Prepandrix™ (Prepandrix™) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated influenza vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated influenza vaccine H5N1 influenza virus surface antigens (hemagglutinin and neuraminidase) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Prepandrix™ (Prepandrix™) — GlaxoSmithKline. Prepandrix is an inactivated split-virion influenza vaccine that stimulates the immune system to produce antibodies against pandemic H5N1 influenza virus strains.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Prepandrix™ TARGET Prepandrix™ GlaxoSmithKline marketed Inactivated influenza vaccine H5N1 influenza virus surface antigens (hemagglutinin and neuraminidase)
Standard IIV4 Standard IIV4 Marshfield Clinic Research Foundation marketed Inactivated influenza vaccine
trivalent seasonal influenza vaccine trivalent seasonal influenza vaccine Sinovac Biotech Co., Ltd marketed inactivated influenza vaccine
Fluzone® (IM) Fluzone® (IM) National Institute of Allergy and Infectious Diseases (NIAID) marketed inactivated influenza vaccine
inactivated split-virus influenza vaccine inactivated split-virus influenza vaccine The Cleveland Clinic marketed inactivated influenza vaccine
Seasonal trivalent vaccine Seasonal trivalent vaccine Sinovac Biotech Co., Ltd marketed Inactivated influenza vaccine
Flublok™ Quadrivalent by Sanofi, Inc. Flublok™ Quadrivalent by Sanofi, Inc. Centers for Disease Control and Prevention marketed Recombinant inactivated influenza vaccine Influenza hemagglutinin (HA) protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated influenza vaccine class)

  1. GlaxoSmithKline · 16 drugs in this class
  2. Seqirus · 5 drugs in this class
  3. Sanofi Pasteur, a Sanofi Company · 5 drugs in this class
  4. Green Cross Corporation · 4 drugs in this class
  5. Novartis · 2 drugs in this class
  6. SK Chemicals Co., Ltd. · 2 drugs in this class
  7. Sanofi · 2 drugs in this class
  8. Hospital Israelita Albert Einstein · 2 drugs in this class
  9. McGill University Health Centre/Research Institute of the McGill University Health Centre · 2 drugs in this class
  10. Il-Yang Pharm. Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prepandrix™ — Competitive Intelligence Brief. https://druglandscape.com/ci/prepandrix. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: